Analytical Data
-
Gene name
UACA
- Application
-
Alternative Names
NUCLING
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BZF9
-
Expression Region
Ala29~Glu209
-
Molecular Weight
23kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UACA (Uveal Autoantigen Component A) is a protein associated with uveal melanoma, a malignant tumor of the eye that poses significant challenges for diagnosis and treatment. Research into UACA has been propelled by its potential role as a biomarker for early detection of uveal melanoma and its implications in immunotherapy. Uveal melanoma is relatively rare but notorious for its aggressive nature and high rate of metastasis, often spreading to the liver, making early intervention crucial. Recent studies have focused on the structural and functional properties of UACA, highlighting its significance in immune responses and tumor microenvironment interactions. The reorganization of UACA protein, through techniques such as crystallography and protein engineering, aims to elucidate its molecular mechanisms and interactions with other cellular components. Understanding these aspects could pave the way for novel therapeutic strategies that harness the immune system to combat this malignancy or improve diagnostic methods to facilitate earlier detection. As research progresses, the exploration of UACA's multifaceted roles in uveal melanoma and other cancer types remains pivotal in the quest for effective cancer management and immunotherapeutic options.
